---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-049436"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2024-04-29T23:59:59+00:00"
generated_at: "2026-06-03T05:40:57.089556+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cullinan Therapeutics hires Mary Kay Fenton as CFO; $495k salary, 200k-share option grant

## Summary
- Mary Kay Fenton appointed CFO effective April 29, 2024; previously CFO of Talaris Therapeutics.
- Annual base salary set at $495,000; target annual bonus of 40% of base salary.
- Received option to purchase 200,000 shares vesting over 4 years (25% one-year cliff).
- Severance: 9 months base salary plus prorated bonus if terminated without cause or for good reason outside CIC period.
- No familial relationship with directors/officers; at-will employment.

## SEC filing metadata
- accession: 0000950170-24-049436
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2024-04-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000095017024049436/0000950170-24-049436-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000095017024049436/cgem-20240429.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-049436
- JSON: https://secwatch.observer/filing/0000950170-24-049436.json
- Plain text: https://secwatch.observer/filing/0000950170-24-049436.txt

## Key facts
- Executive change
  Mary Kay Fenton was appointed as Chief Financial Officer at Cullinan Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On April 29, 2024, Cullinan Therapeutics, Inc. (the “Company”) announced the hiring and appointment of Mary Kay Fenton as the Company’s Chief Financial Officer, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789972/000095017024049436/0000950170-24-049436-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.